Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Cerovene Inc.
EIR
•Cerovene Inc.•February 8, 2017

Cerovene Inc. – FDA EIR, Feb 8, 2017

Record Details

An FDA pre-approval inspection of Cerovene, Inc., a prescription drug manufacturer located in Valley Cottage, NY, took place from January 26 to February 8, 2017. The inspection, conducted under CPGM 7356.002 and 7346.832, aimed to assess the firm's readiness for commercial manufacturing of NDA 209777, Oxycodone HCl Abuse-Resistant Immediate Release Tablets. Key findings led to an FDA-483 observation primarily concerning inadequate equipment qualification of the tablet coating machine. Cerovene failed to properly document critical details like core tablet weight, size, and appearance during performance qualification (PQ) studies. Moreover, the coating machine was not adequately challenged across the full operating range planned for commercial batch sizes during the qualification process. Further deficiencies were verbally communicated, including the quality unit's insufficient review of records, notably regarding outdated calibration certificates for qualification devices and inconsistencies in HPLC audit trails, such as unexplained "trial" injections and re-injections. The inspection also identified missing manufacturing and in-process sampling instructions in master batch records, and an inadequate system for tracking out-of-specification (OOS) results from system suitability test failures. Cerovene management acknowledged these observations, providing a written commitment to address the issues. The firm pledged to submit a formal response to the FDA-483 within 15 business days, conduct additional performance qualification for the coating machine, implement corrective and preventive actions (CAPA 2017-001) to enhance laboratory data control, and revise standard operating procedures for OOS tracking. The proposed corrective measures will be reviewed by the FDA's Center for Drug Evaluation and Research (CDER) and the Compliance Branch for adequacy.

Company
Cerovene Inc.
Inspection date
February 8, 2017
Product type
drugs
Office
New York District Office
Person
  • Mindy M. Chou
View Company Profile

ID · 6b43fa69-a67c-4868-a284-629aaaa292ca

Violation Codes1
21 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for Cerovene Inc.
  • 483 - 2026-03-23March 23, 2026
  • 483 - 2025-04-28April 28, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cerovene Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.